Elosulfase alfa for the treatment of mucopolysacchoridosis IVA

References

• Tanpaiboon P, Lopez G. Lysosomal storage disorders and epilepsy. In: Phillip L Pearl, Inherited Metabolic Epilepsies. Demos Medical Publishing, LLC; New York: 2013. 287-316
   Google Scholar
• Montano AM, Tomatsu S, Gottesman GS, et al. International Morquio A registry: Clinical manifestation and natural course of Morquio A disease. J Inherit Metab Dis 2007;30:165-74
   PubMed Web of Science ®Google Scholar
• Harmatz P, Mengel KE, Giugliani R, et al. The Morquio A clinical assessment program: Baseline results illustrating progressive, multisystemic clinical impairments in Morquio A subjects. Mol Genet Metab 2013;109:54-61
   PubMed Web of Science ®Google Scholar
• Harmatz PR, Mengel KE, Giugliani R, et al. Longitudinal analysis of endurance and respiratory function from a natural history study of Morquio A syndrome. Mol Genet Metab 2015;114:186-94
   PubMed Web of Science ®Google Scholar
• Valayannopoulos V, Wijburg FA. Therapy for the mucopolysaccharidoses. Rheumatology supp 2011;5:v49-59
   Web of Science ®Google Scholar
• Gabrielli O, Clarke LA, Bruni S, Coppa CV. Enzyme replacement therapy in a 5-month-old boy with attenuated presymptomatic MPS I-5 year follow up. Pediatrics 2010;125:e183-7
   PubMed Web of Science ®Google Scholar
• Harmatz P, Garcia N, Guffon LM. Galsulfase (Naglazyme) therapy in infants with mucopolysaccharidosis VI. J Inherit Metab Dis 2014;37:277-87
   PubMed Web of Science ®Google Scholar
• Regier DS, Oetgen M, Tanpaiboon P. Mucopolysaccharidosis Type IVA. 2013; In: Pagon RA, Adam MP, Bird TD, et al. editors. GeneReviews™ [Internet]. Seattle (WA): University of Washington: Seattle; 1993-2013. Available from: www.ncbi.nlm.nih.gov/books/NBK148668/. [Last accessed 6 October 2014]
   Google Scholar
• Chinen Y, Higa T, Tomatsu S, et al. Long-term therapeutic efficacy of allogenic bone marrow transplantation in a patient with mucopolysaccharidosis IVA. Mol Genet Metab Rep 2014;1:31-41
   PubMedGoogle Scholar
• Tanpaiboon P. Lysosomal Storage Disorders. J Ped Biochem 2014;4(4):217-29
   Google Scholar
• BioMarin Pharmaceutical. Vimizim (elosulfase alfa) for the treatment of mucopolysaccharidosis type IVA (Morquio syndrome): briefing document for the endocrinologic and metabolic drugs advisory committee. 2013. Available from: www.fda.gov/downloads/advisorycommittees/committeesmeetingmaterials/drugs/endocrinologicandmetabolicdrugsadvisorycommittee/ucm375127.pdf [Last accessed 1 April 2015]
   Google Scholar
• BioMarin Pharmaceutical Inc. Vimizim (elosulfase alpha) injection, for intravenous use: US prescribing information. 2014. Available from: www.accessdata.fda.gov/drugsatfda_docs/label/2014/1254 60s000lbl.pdf [Last accessed 30 November 2014]
   Google Scholar
• Dvorak-Ewell M, Wendt D, Hague C, et al. Enzyme replacement in a human model of mucopolysaccharidosis IVA in vitro and its biodistribution in the cartilage of wild type mice. PLoS One 2010;5(8):e12194
   PubMed Web of Science ®Google Scholar
• Hendriksz CJ, Burton B, Fleming TR, et al. Efficacy and safety of enzyme replacement therapy with BMN110 (elosulfase alfa) for Morquio A syndrome (mucopolysaccharidosis IVA): a phase 3 randomized placebo-controlled study. J Inherit Metab Dis 2014;37:979-90
   PubMed Web of Science ®Google Scholar
• Qi Y, Musson DG, Schweighardi B, et al. Pharmacokinetic and pharmacodynamics evaluation of Elosulfase alfa, an enzyme replacement therapy in patients with Morquio A syndrome. Clin Pharmacokinet 2014;53:1137-47
   PubMed Web of Science ®Google Scholar
• Burton KB, Berger KI, Lewis GD, et al. Safety and physiological effects of two different doses of elosulfase alfa in patients with Morquio A syndrome: A randomized, double-blind, pilot study. Am Genet Med Genet A 2015. [Epub ahead of print]
   Google Scholar
• Schweighardt B, Tompkins T, Lau K, et al. Immunogenicity of elosulfase alfa, an enzyme replacement therapy in patients with Morquio A syndrome: results from MOR-004, a phase III trial. Clin Ther 2014; [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Tomatsu S, Montaño AM, Ohashi A, et al. Enzyme replacement therapy in a murine model of Morquio A syndrome. Hum Mol Genet 2008;17(6):815-24
   PubMed Web of Science ®Google Scholar
• Tomatsu S, Sawamoto K, Almeciga-Diaz CJ, et al. Impact of enzyme replacement therapy and hematopoietic stem cell transplantation in patients with Morquio A syndrome. Drug Des Devel Ther 2015;9:1937-53
   PubMed Web of Science ®Google Scholar
• Hendriksz CJ, Giugliani R, et al. Multi-domain impact of elosulfase alfa in Morquio A syndrome in the pivotal phase III trial. Mol Genet Metab 2015;114:178-85
   PubMed Web of Science ®Google Scholar
• Clinicaltrials.gov. Available from: www.clinicaltrials.gov [Last accessed 29 April 2015]
   Google Scholar
• U.S. department of health and human services, National Cancer Institute, National Institutes of Heatlh. Common terminology criteria for adverse events (CTCAE) version 4.0, 2009
   Google Scholar
• Goldenberg MM. Pharmaceutical approval update. P&T 2014;39:337-8
   PubMedGoogle Scholar
• The National Institute for Health and Care Excellence (NICE). NICE asks company for further information on drug for rare inherited disease in draft guidance. Available from: www.nice.org.uk/news/press-and-media/nice-asks-company-for-further-information-on-drug-for-rare-inherited-disease-in-draft-guidance [Last accessed 15 August 2015]
   Google Scholar
• Tomatsu S, Almeciga-Diaz CJ, Montano AM. Therapies for the bone in mucopolysaccharidoses. Mol Genet Metab 2015;114:94-109
   PubMed Web of Science ®Google Scholar
• Donida B, Marchetti DP, Biancini GB, et al. Oxidative stress and inflammation in mucopolysaccharidosis type IVA patients treated with enzyme replacement therapy. Biochim Biophys Acta 2015;1852:1012-19
   PubMed Web of Science ®Google Scholar
• Francyne K, Shimada T, Mason RW, et al. Analysis of C6S/C4S ratio in Morquio syndrome type A patients. Mol Genet Metab 2015;114:S66
   PubMedGoogle Scholar
• Francyne K, Shimada T, Tomatsu S, et al. Chondroitin 6 sulfate as a novel biomarker for mucopolysaccharidosis IVA and VII. Mol Genet Metab 2015;114:S66
   PubMedGoogle Scholar
• Francyne K, Shimada T, Tomatsu S, et al. Di-sulfated keratin sulfate as a novel biomarker for mucopolysaccharidosis IVA. Mol Genet Metab 2015;114:S66-7
   PubMedGoogle Scholar